Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Curve Therapeutics

Request full access

Redefining drug discovery in order to make it more efficient and effective

Southampton, United KingdomFounded 2019Biotech & Life Sciences

About Curve Therapeutics

Curve Therapeutics, founded in 2019 as a spin-out from the University of Southampton, is a biotechnology firm focused on developing a new class of medicines for complex diseases, with an initial emphasis on oncology. The company's genesis lies in over a decade of research by its co-founder, Professor Ali Tavassoli, within the university's Department of Chemistry. Professor Tavassoli, now the Chief Scientific Officer, is a Professor of Chemical Biology whose research has centered on creating high-throughput screening platforms to discover inhibitors of protein-protein interactions. He is joined by co-founder and CEO, Dr. Simon Kerry, a life-science entrepreneur with over three decades of leadership experience in European biotech companies, including roles at Karus Therapeutics, Ablynx, and Advent Life Sciences.

The core of Curve Therapeutics' operations is its proprietary Microcycle® platform. This technology enables the direct functional screening of vast, genetically encoded libraries of cyclic peptides within live mammalian cells. This intracellular screening method is a key differentiator, as it allows for the identification of active molecules against challenging targets in their natural cellular environment, a feat difficult to achieve with conventional drug discovery techniques. The platform is designed to identify molecules that can modulate historically 'undruggable' targets, such as protein-protein and protein-DNA interactions, which are implicated in numerous cancers. The small, rigid structure of the identified Microcycles facilitates their subsequent development into small molecule drugs.

The company's business model is twofold, involving both in-house pipeline development and strategic collaborations with major pharmaceutical companies. A significant milestone is a global research collaboration with MSD (the trade name of Merck & Co., Inc.) potentially worth up to $1.7 billion, focused on discovering and validating modulators for up to five therapeutic targets in oncology and neurology. Curve Therapeutics has also built its own discovery pipeline, featuring assets like a first-in-class dual inhibitor of HIF-1 and HIF-2, which targets survival mechanisms in a majority of solid tumors, and an inhibitor of ATIC dimerization. To advance these programs, the company secured £40.5 million in a Series A financing round in February 2024, led by Pfizer Ventures and supported by investors such as British Patient Capital, Columbus Venture Partners, Advent Life Sciences, and Epidarex Capital.

Source: Dealroom company data

At a glance

Status
Operational
Employees
36
Open positions
None listed
Dealroom signal
72.3/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Microfluidics, Core AI, Spinout, AI Drug Discovery, Techbio, Techbio Drug Discovery, AI Applications, Digital Pharma, DT and LS
Technology
Artificial Intelligence
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES AOther financing Feb 2024 $53M $214M Epidarex Capital · Columbus Venture Partners · Advent Life Sciences · British Patient Capital ↗
SPINOUTOther financing May 2019 $0 — University of Southampton —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Curve Therapeutics website traffic

Latest recorded traffic for Curve Therapeutics is 210 monthly website visits, down 90.5% over the last three months. Curve Therapeutics's team declined 2.7% over the past year.

Latest monthly visits210 3-month web change-90.5% 1-year team growth-2.7%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Curve Therapeutics in the Southampton ecosystem

Live from Dealroom

The Curve Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A5 investors entered at this stage

  • Epidarex Capital
  • Columbus Venture Partners
  • Advent Life Sciences
  • British Patient Capital
  • Pfizer Ventures

Other known investors1 additional known investor

  • University of Southampton
Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇬🇧 United Kingdom88.2%
🇺🇸 United States8.8%
🇪🇸 Spain2.9%
3 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Curve Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Curve Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.